Lives unaffected by cystic fibrosis

Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • ObservationalEnrolling Location: Queensland University of Technology Contact: Jeremy Russell - phone:07 3069 7552 email: [email protected] To get started, go to: https://rebrand.ly/HYPRS-CF

    Helping Young People Reduce the Stress of Cystic Fibrosis Study , protocol number The HYPRS-CF Study 1800000294 (UHREC Reference number)

    Researchers at QUT are conducting a national, online research study with young people with Cystic Fibrosis (CF). The goal of this study is to learn how young people think and feel about the stress of CF and whether a social robot could possibly help them cope with this stress.

    • Age:

      10-18 years

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      No FEV1 limit

    • Number of Visits:

      1

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple care centres across the U.S.

    Study of VX-445 triple combination in teens and adults with cystic fibrosis who have one copy of F508del and one copy of a gating or residual function mutation , protocol number NCT04058353 VX18-445-104

    This study will look at the safety and effectiveness of three CFTR modulators when taken in combination: VX-445 (elexacaftor), tezacaftor and ivacaftor. CFTR modulators are drugs intended to help CFTR protein function closer to normal.

    • Age:

      12 Years and older

    • Mutation(s):

      One Copy F508del

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      8

    • Length of Participation:

      20 weeks

    Contact us about this clinical Trial >
  • Mucociliary ClearanceCompleted with results Location: Multiple care centres across the US

    Study of QBW276 in adults with CF , protocol number NCT92566044 NOVARTIS CQBW 276X2201

    This study evaluated the safety and tolerability of QBW276, an inhaled drug designed to improve mucus clearance. This study also evaluated how the body processes the drug.

    • Age:

      18 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      40 to 100%

    • Number of Visits:

      6

    • Length of Participation:

      14 days

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: Multiple care centres across the US

    Roll-over study of ivacaftor in children with CF who have a CFTR gating mutation (Vertex VX-770-109) , protocol number NCT01946412 VERTEX VX-770-109

    This study evaluated the long-term safety of ivacaftor (Kalydeco®) in children with CF. This study was for children who have a CFTR gating mutation and received at least one dose of ivacaftor in the VX11-770-108 study.

    • Age:

      2 years to 5 years

    • Mutation(s):

      One Copy F508del or No Copies F508del

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      7

    • Length of Participation:

      88 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: Multiple care centres across the US

    Open-label study of ivacaftor in people with CF who have a non-G551D CFTR gating mutation (Vertex VX-770-112) , protocol number NCT01707290 VERTEX VX-770-112

    This study evaluated the long-term safety of ivacaftor (Kelydeco®) in participants who have a non-G551D CFTR gating mutation. This study was for people who had participated in one of the VX11-770-110, VX12-770111 or VX12-770-113 studies.

    • Age:

      6 Years and Older

    • Mutation(s):

      One Copy F508del or No Copies F508del

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      7

    • Length of Participation:

      2 years

    Contact us about this clinical Trial >
  • Mucociliary ClearanceEnrolling Location: Florida, USA

    Study of BI 1265162, a mucus clearance drug, in teens and adults with CF. , protocol number NCT04059094 BI 1399-0003

    This study will look at the safety and effectiveness of BI 1265162, a drug intended to improve the clearance of mucus from the lungs. This study is for people with CF ages 12 and older.

    • Age:

      12 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      5

    • Length of Participation:

      7 weeks

    Contact us about this clinical Trial >
  • ObservationalEnrolling Location: Multiple care centres across the US

    Study to evaluate the effects of the triple-combination modulator, elexacaftor/texacaftor/ivacaftor (PROMISE) , protocol number NCT04038047 PROMISE

    This observational study will measure the effects of the triple-combination therapy, elexacaftor/tezacaftor/ivacaftor, in people with CF. These drugs are intended to help CFTR protein function closer to normal. This study will look at how treatment with the triple-combination therapy affects people with CF across many different aspects of the disease.

    • Age:

      12 Years and Older

    • Mutation(s):

      Two Copies F508del or One Copy F508del

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      6

    • Length of Participation:

      2 years

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple care centres across the US

    Phase 2 study of PTI-808 triple-combination therapy in adults with cystic fibrosis who have at least one copy of the F508del mutation. , protocol number NCT03251092 PTI-808

    This study will look at the safety and tolerability of PTI-808, a modulator intended to help CFTR protein function closer to normal. PTI-808 will be tested in combination with two other modulators, PTI-801 and PTI-428.

    • Age:

      18 Years and Older

    • Mutation(s):

      Two copies F508del or One Copy F508del

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      9

    • Length of Participation:

      10 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple care centres across the US

    Study of ABBV-3067 and ABBV-2222 in adults with cystic fibrosis who have two copies of the F508del mutation. , protocol number NCT03969888 AbbVie ABBV-3067

    This study will look at the safety and effectiveness of ABBV-3067, a CFTR modulator intended to help CFTR protein function closer to normal. ABBV-3067 will be tested alone and in combination with another CFTR modulator, ABBV-2222. This study has two parts. In Part 1, participants will be randomly assigned to receive one of the following treatments: the study drug ABBV-3067 alone; both ABBV-3067 and ABBV-2222; or a placebo. In Part 2 of the study, some participants will receive both CFTR modulators ABBV-3067 and ABBV-2222, and some participants will receive a placebo. Researchers will test the effectiveness of ABBV-3067 alone and in combination with ABBV-2222 by measuring changes in lung function and sweat chloride. This study may require lung function tests and/or other measurements.

    • Age:

      18 years and Older

    • Mutation(s):

      Two Copies F508del

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      5

    • Length of Participation:

      3 months

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple care centres across the US

    Study to evaluate VX-121 in adults 18 years and older with cystic fibrosis , protocol number NCT03912233 VERTEX VX-18-121-101

    This study will look at the safety, tolerability, and effectiveness of the drug VX-121, a drug intended to help CFTR function closer to normal. This study will take place in two parts. Part 1 is randomized and placebo-controlled. This means that some participants will receive the study drug in combination with tezacaftor and VX-561, and some participants will receive placebo. Part 2 is a randomized, active-comparator trial. This means that some participants will receive the study drug in combination with tezacaftor and VX-561, and some participants will receive placebo in combination with tezacaftor and ivacaftor. In this study, researchers will test the safety and tolerability by monitoring for adverse events. They will test for effectiveness by measuring lung function. They will also monitor sweat chloride and how much of the drug stays in the body. This study may require sweat tests, lung function tests, blood samples and/or other measures.

    • Age:

      18 years and Older

    • Mutation(s):

      Two Copies F508del or One Copy F508del

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      10

    • Length of Participation:

      17 weeks

    Contact us about this clinical Trial >
  • Displaying results 71-80 (of 178)
     |<  <  4 - 5 - 6 - 7 - 8 - 9 - 10 - 11 - 12 - 13  >  >|